Clay Siegall, Morphimmune CEO (Photo by Dimitrios Kambouris/Getty Images for Gabrielle's Angel Foundation)
Shortly after Clay Siegall’s arrival, Philip Low’s Morphimmune nabs funds for twist on cancer therapies
Two months after announcing Clay Siegall’s arrival in the C-suite, Morphimmune has nabbed more funds to take its targeted cancer therapy bet toward the clinic.
The fledgling biotech filed a $15 million equity round, from 11 investors, with the SEC this week. Morphimmune did not respond to Endpoints News as of publication time. The financing comes through as Siegall settles into his first post-Seagen role as CEO, president and board member of Morphimmune.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters